Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 12/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484652 | 0.89 | CYP46A1 (0.59) | CYP46A1HTR1AP2RX7DRD2DRD4 | |
| SCHEMBL24484276 | 0.88 | CYP46A1 (0.49) | CYP46A1HTR1AP2RX7DRD2DRD4 | |
| SCHEMBL24484673 | 0.88 | CYP46A1 (0.46) | CYP46A1HTR1ADRD2DRD4DRD3 | |
| SCHEMBL24484614 | 0.85 | HTR1A (0.45) | CYP46A1HTR1ADRD2DRD4DRD3 | |
| SCHEMBL26081269 | 0.84 | CYP46A1 (0.44) | CYP46A1HTR1AP2RX7DRD2DRD4 | |
| SCHEMBL24484700 | 0.84 | CYP46A1 (0.44) | CYP46A1HTR1AP2RX7DRD2DRD4 | |
| SCHEMBL24484617 | 0.80 | CYP46A1 (0.47) | CYP46A1HTR1ADRD2DRD4DRD3 | |
| SCHEMBL24484707 | 0.79 | CYP46A1 (0.60) | CYP46A1HTR1ADRD2DRD4DRD3 | |
| SCHEMBL24484231 | 0.78 | CYP46A1 (0.62) | CYP46A1HTR1AP2RX7 | |
| SCHEMBL24484620 | 0.78 | CYP46A1 (0.61) | CYP46A1HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2022115620-A1 | 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP46A1 1/4885HTR1A 1004/4885P2RX7 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.